Anna Tyler

Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.

Stephen J. Thomas, N. Michael, D. Barouch, 2020, The Lancet. Infectious diseases.

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate given via standard versus accelerated vaccination schedules: a phase 1, single-center, double-blind, sequential-group, randomized, placebo-controlled clinical trial

Joseph, N. Michael, D. Barouch, 2020 .

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Ahmed Abdul Azim, D. Lauffenburger, H. Schuitemaker, 2021, JAMA.

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).

H. Schuitemaker, G. Alter, F. Wegmann, 2020, The lancet. HIV.

Immunologic resilience and COVID-19 survival advantage

Peter B Polk, R. E. Phillips, D. Richman, 2021, Journal of Allergy and Clinical Immunology.